Reckitt CEO's $17B Predicament Post author:Sam Post published:December 26, 2017 Post category:BioPharma 2018 is the year for Rakesh Kapoor to show he’s worth it. Source: BioSpace You Might Also Like Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. January 19, 2017 Ceapro Reports 2016 Financial Results And Provides Corporate Update April 5, 2017 Massachusetts' Haemonetics to Eliminate 350 Jobs November 6, 2017
Karolinska Development AB Release: Pharma Portfolio Company Announces FDA 510(K) Clearance For Marketing Of OSSDSIGN Cranial For Sale In The U.S.A. January 19, 2017
